triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
=== In the United Kingdom === Based on Appert's methods of food preservation, the tin can process was allegedly developed by Frenchman Philippe de Girard, who came to London and used British merchant Peter Durand as an agent to patent his own idea in 1810. Durand did not pursue food canning himself, selling his patent in 1811 to Bryan Donkin and John Hall, who were in business as Donkin Hall and Gamble, of Bermondsey. Bryan Donkin developed the process of packaging food in sealed airtight cans, made of tinned wrought iron. Initially, the canning process was slow and labour-intensive, as each large can had to be hand-made, and took up to six hours to cook, making canned food too expensive for ordinary people. The main market for the food at this stage was the British Army and Royal Navy. By 1817, Donkin recorded that he had sold £3000 (equal to £222,201 today) worth of canned meat in six months. In 1824, Sir William Edward Parry took canned beef and pea soup with him on his voyage to the Arctic in HMS Fury, during his search for a northwestern passage to India. In 1829, Admiral Sir James Ross also took canned food to the Arctic, as did Sir John Franklin in 1845. Some of his stores were found by the search expedition led by Captain (later Admiral Sir) Leopold McClintock in 1857.
== June 28, 1915 (Monday) == British cargo ship Armenian was torpedoed and sunk in the Atlantic Ocean by German ship SM U-24 with the loss of 29 crew. Survivors were rescued by a Belgian cargo ship. Battle of Gully Ravine — British forces attacked and captured key defense positions from the Ottoman Empire in Gallipoli that advanced the left flank of the British line closest to the Aegean Sea. Rapid snow melt in the Rockies and heavy rain caused the North Saskatchewan River to overflow in Alberta. River levels in Edmonton were reported to be rising over 10 feet. In the order to prevent the Low Level Bridge — the only available crossing over the river at the time — from being broken apart by river debris, Canadian Northern Railway parked several train cars on the bridge to bolster its weight. Some housing and several lumber mills in the river valley were swept away by the flooding. Died: Guillermo Billinghurst, 63, Peruvian state leader, third President of Peru (b. 1851) Victor Trumper, 37, Australian cricketer, batsman for the Australia national cricket team from 1898 to 1912 and the New South Wales cricket team from 1894 to 1914; died of Bright's disease (b. 1877) Charles Spagnoletti, 82, British engineer, first superintendent for the Great Western Railway telegraph; died of pneumonia (b. 1832)
=== Robin Williamson === Robin Williamson (Jonjo O'Neill) is the chief communications officer at Tender, assisting Whitney in pivoting the company into banking. During the launch of Tender's banking app, Robin clashes with Yasmin over their dueling PR strategies, with Robin preferring a more traditional rollout via tech publications and podcasts, while Yasmin seeks to capitalize on Henry Muck's profile as CEO by booking him a keynote speech. Yasmin's approach wins over Whitney, who promotes Yasmin to head of communications and fires Robin, deeming him too traditional and risk-averse.
Sources: en.wikipedia.org
Many of the payloads for oncology ADCs (oADC) are natural product based with some making covalent interactions with their target. Payloads include the microtubulin inhibitors monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and mertansine, DNA binder calicheamicin and topoisomerase 1 inhibitors SN-38 and exatecan resulting in a renaissance for natural product total synthesis. Glucocorticoid receptor modulators (GRMs) represent to most active payload class for iADCs. Approaches releasing marketed GRM molecules such as dexamethasone and budesonide have been developed. Modified GRM molecules have also been developed that enable the attachment of the linker with the term ADCidified describing the medicinal chemistry process of payload optimization to facilitate linker attachment. Alternatives to small molecule payloads have also been investigated, for example, siRNA. More recently, targeted protein degraders have been explored as payloads for antibody conjugates. A 2025 study described a KIF11-directed degrader–antibody conjugate (DAC), in which a cereblon-recruiting degrader was used as the payload to induce antigen-dependent protein degradation and cytotoxicity in preclinical models.
== Radioactivity over time == Fission products have half-lives of 90 years (samarium-151) or less, except for seven long-lived fission products that have half-lives of 211,100 years (technetium-99) or more. Therefore, the total radioactivity of a mixture of pure fission products decreases rapidly for the first several hundred years (controlled by the short-lived products) before stabilizing at a low level that changes little for hundreds of thousands of years (controlled by the seven long-lived products). This behavior of pure fission products with actinides removed, contrasts with the decay of fuel that still contains actinides. This fuel is produced in the so-called "open" (i.e., no nuclear reprocessing) nuclear fuel cycle. A number of these actinides have half-lives in the missing range of about 100 to 200,000 years, causing some difficulty with storage plans in this time-range for open-cycle non-reprocessed fuels. Proponents of nuclear fuel cycles which aim to consume all their actinides by fission, such as the Integral Fast Reactor and molten salt reactor, use this fact to claim that within 200 years, their fuel wastes are no more radioactive than the original uranium ore. Fission products primarily emit beta radiation, while actinides primarily emit alpha radiation. Many of each also emit gamma radiation.
=== Pharmacokinetics === After oral intake, ertugliflozin is practically completely absorbed from the gut and undergoes no relevant first-pass effect. Highest blood plasma concentrations are reached after one hour. When in circulation, 93.6% of the substance are bound to plasma proteins. Ertugliflocin is metabolised mainly to glucuronides by the enzymes UGT1A9 and UGT2B7. Cytochrome P450 enzymes play only a minor role in its metabolism. The elimination half-life is estimated to be 17 hours. 40.9% are eliminated via the feces (33.8% in unchanged form and 7.1% as metabolites) and 50.2% via the urine (1.5% unchanged and 48.7% as metabolites). The high proportion of unchanged substance in the feces is probably due to hydrolysis of the metabolites back to the parent substance.
Sources: en.wikipedia.org
metabolic pathway A stepwise series of biochemical reactions occurring within a cell, often but not necessarily catalyzed by specific enzymes, that fulfills some activity or process related to metabolism. The reactions are linked by the sharing of reactants, products, or intermediate compounds in consecutive steps, such that the product of one reaction is used as a reactant in a subsequent reaction. Byproducts are often removed from the cell as metabolic waste. The overall pathway may be anabolic, catabolic, or amphibolic in nature. In any actively metabolizing cell, an elaborate network of interconnected metabolic pathways is required to maintain homeostasis, with degradative catabolic processes providing the energy necessary to conduct anabolic biosynthesis; for example, glycolysis, the electron transport chain, and oxidative phosphorylation provide the ATP used in fatty acid synthesis. The flux of metabolites through each pathway is regulated by the needs of the cell and the availability of substrates.
== Applications == Some polyphenols are traditionally used as dyes in leather tanning. For instance, in the Indian subcontinent, pomegranate peel, high in tannins and other polyphenols, or its juice, is employed in the dyeing of non-synthetic fabrics. Of some interest in the era of silver-based photography, pyrogallol and pyrocatechin are among the oldest photographic developers.
== History == In 1902 Victor Henri proposed a quantitative theory of enzyme kinetics, but at the time the experimental significance of the hydrogen ion concentration was not yet recognized. After Peter Lauritz Sørensen had defined the logarithmic pH-scale and introduced the concept of buffering in 1909, the German chemist Leonor Michaelis and Dr. Maud Leonora Menten (a postdoctoral researcher in Michaelis's lab at the time) repeated Henri's experiments and confirmed his equation, which is now generally referred to as Michaelis-Menten kinetics (sometimes also Henri-Michaelis-Menten kinetics). Their work was further developed by G. E. Briggs and J. B. S. Haldane, who derived kinetic equations that are still widely considered today a starting point in modeling enzymatic activity. The major contribution of the Henri-Michaelis-Menten approach was to think of enzyme reactions in two stages. In the first, the substrate binds reversibly to the enzyme, forming the enzyme-substrate complex. This is sometimes called the Michaelis complex. The enzyme then catalyzes the chemical step in the reaction and releases the product. The kinetics of many enzymes is adequately described by the simple Michaelis-Menten model, but all enzymes have internal motions that are not accounted for in the model and can have significant contributions to the overall reaction kinetics. This can be modeled by introducing several Michaelis-Menten pathways that are connected with fluctuating rates, which is a mathematical extension of the basic Michaelis Menten mechanism.
He helped to revive the Ginsberg crèche, a daycare for children of working mothers, and establish a Ginsberg education fund to raise bursaries for promising local students. He helped establish Njwaxa Home Industries, a leather goods company providing jobs for local women. In 1975, he co-founded the Zimele Trust, a fund for the families of political prisoners. Biko endorsed the unification of South Africa's black liberationist groups – among them the BCM, PAC, and African National Congress (ANC) – in order to concentrate their anti-apartheid efforts. To this end, he reached out to leading members of the ANC, PAC, and Unity Movement. His communications with the ANC were largely via Griffiths Mxenge, and plans were being made to smuggle him out of the country to meet Oliver Tambo, a leading ANC figure. Biko's negotiations with the PAC were primarily through intermediaries who exchanged messages between him and Sobukwe; those with the Unity Movement were largely via Fikile Bam.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.